Loading...
XNAS
TXMD
Market cap20mUSD
Dec 05, Last price  
1.74USD
1D
8.07%
1Q
61.11%
Jan 2017
-99.40%
IPO
-96.30%
Name

TherapeuticsMD Inc

Chart & Performance

D1W1MN
XNAS:TXMD chart
P/E
P/S
11.44
EPS
Div Yield, %
Shrs. gr., 5y
18.54%
Rev. gr., 5y
-48.72%
Revenues
2m
+35.25%
934,5251,005,2740010,56948,2172,088,1773,818,0138,775,59815,026,21920,142,89819,356,45016,777,71316,099,46049,646,93764,872,28086,951,00069,963,0001,302,0001,761,000
Net income
-2m
L-78.78%
289,887373,015170,542-395,553-1,654,541-695,375-12,913,365-35,120,235-28,419,313-54,217,210-85,077,024-89,875,459-76,925,380-132,617,160-196,027,320-212,702,827-205,604,000111,997,000-10,278,000-2,181,000
CFO
1m
P
412,339329,840344,098-133,003-417,338836,832-4,966,596-12,737,326-20,768,069-45,520,996-79,044,119-69,142,333-76,155,614-106,811,781-165,697,595-159,470,335-142,693,000-4,078,000-48,141,0001,170,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
IPO date
Jan 31, 2001
Employees
1
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT